Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Schering) in the assessment of response to neo-adjuvant treatment with bevacizumab (Avastin) of liver metastases in patients with colorectal cancer

Trial Profile

Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Schering) in the assessment of response to neo-adjuvant treatment with bevacizumab (Avastin) of liver metastases in patients with colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Gadofosveset (Primary) ; Gadopentetic acid
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top